Abstract 6073
Background
Thyroid carcinomas are fairly uncommon tumors. They include disease types that range from indolent behavior such as papillary carcinomas to the fulminant and lethal anaplastic disease. The aim of this study was to analyze the characteristics of patients diagnosed with thyroid carcinoma in the United States between 2000 till 2016.
Methods
This study was conducted using SEER*Stat version 8.3.5 to analyze clinical and pathological characteristics of thyroid carcinoma patients diagnosed in the period between 2000 and 2016 in the United States through exploiting the data obtained from SEER Regs Research Data Nov 2018. The data were statistically analyzed using SPSS version 20.
Results
A total of 172525 cases of thyroid carcinoma were diagnosed. The median age at diagnosis was 50 years. Females were the most common gender affected (n = 131059; 75.7%). The incidence rate of thyroid carcinoma was estimated to be 12 per 100,000 cases. Papillary adenocarcinoma, NOS was the most common histology (n = 84323; 48.7%), followed by follicular variant of papillary carcinoma (n = 46830, 27.1%). The disease was the only primary tumor in most of cases (n = 139831; 80.8%). The majority of patients had localized early disease at the time of diagnosis (Stage I = 89235; 51.5%), and surgery was performed in the vast majority of case (n = 164742; 95.2%). The median survival wasn’t reached, with observed survival, at 5 and 10 years, was 94.2% & 89.2% respectively and relative survival at 5 and 10 years was 98% & 97.4%, respectively.
Conclusions
Thyroid carcinoma is a disease of middle ages, mainly, with female predominance. Papillary thyroid carcinoma is the most common histology and most of patients tend to present at early stage. The survival is good with median survival wasn’t reached and relative 5- year and 10- year survival of 98% & 97.4%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract